Information Provided By: 
Fly News Breaks for May 22, 2017
MYL, MNTA
May 22, 2017 | 05:36 EDT
Barclays analyst Douglas Tsao downgraded Momenta Pharmaceuticals (MNTA) to Equal Weight citing the likelihood of generic manufacturers, most notably Mylan (MYL), winning approval for generic Copaxone in the coming months. The approvals could come before Momenta and its partner Sandoz win approval themselves for the 40mg dose, Tsao tells investors in a research note. He lowered his price target for the shares to $17 from $20.
News For MNTA;MYL From the Last 2 Days
There are no results for your query MNTA;MYL
